Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Programme
Postgraduate Teaching
Industry
Supporters
CME Accreditation
Congress Resources
UEG Week on-demand
Future UEG Weeks
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Start-up Grant
Research Prize
Research Fellowship
Research Webinars
Research Projects
HoloSurge
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
How to develop guidelines
Funding for guideline updates
Guideline Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Support
Start-up Grant
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Remo Panaccione
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
Remo Panaccione
et al.
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Remo Panaccione
et al.
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED 1 VS >1 PRIOR BIOLOGIC TREATMENT: RESULTS FROM THE MOTIVATE STUDY
Remo Panaccione
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
Remo Panaccione
et al.
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
Remo Panaccione
et al.
Opening the door to emerging investigational treatments in ulcerative colitis: What awaits us? (Arena Pharmaceuticals)
Remo Panaccione
et al.
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
Remo Panaccione
et al.
LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
Remo Panaccione
et al.
Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Broadening the horizon of CD: where are we, where are we going and what role could IL-23 play?
Remo Panaccione
Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Welcome and introduction
Remo Panaccione
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
Remo Panaccione
et al.
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
Remo Panaccione
et al.
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
Remo Panaccione
et al.
EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
Remo Panaccione
et al.
Item 1 - 20 / 82
1
2
3
4
5
Chat with us
, powered by
LiveChat